Will Posttranslational Modifications of Brain Proteins Provide Novel Serological Markers for Dementias?
المؤلفون المشاركون
Zheng, Q.
Zhang, C.
Karsdal, Morten A.
Sørensen, M. G.
Wang, Y.
Henriksen, K.
المصدر
International Journal of Alzheimer's Disease
العدد
المجلد 2012، العدد 2012 (31 ديسمبر/كانون الأول 2012)، ص ص. 1-9، 9ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2012-06-21
دولة النشر
مصر
عدد الصفحات
9
التخصصات الرئيسية
الملخص EN
Drug development for dementias is significantly hampered by the lack of easily accessible biomarkers.
Fluid biomarkers of dementias provide indications of disease stage, but have little prognostic value, cannot detect early pathological changes, and can only be measured in CSF (cerebrospinal fluid) which significantly limits their applicability.
In contrast, imaging based biomarkers can provide indications of probability of disease progression, yet are limited in applicability due to cost, radiation and radio-tracers.
These aspects highlight the need for other approaches to the development of biomarkers of dementia, which should focus on not only providing information about pathological changes, but also on being measured easily and reproducibly.
For other diseases, focus on development of assays monitoring highly specific protease-generated cleavage fragments of proteins has provided assays, which in serum or plasma have the ability to predict early pathological changes.
Proteolytic processing of brain proteins, such as tau, APP, and α-synuclein, is a key pathological event in dementias.
Here, we speculate that aiming biomarker development for dementias at detecting small brain protein degradation fragments of generated by brain-derived proteases specifically in blood samples could lead to the development of novel markers of disease progression, stage and importantly of treatment efficacy.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Wang, Y.& Sørensen, M. G.& Zheng, Q.& Zhang, C.& Karsdal, Morten A.& Henriksen, K.. 2012. Will Posttranslational Modifications of Brain Proteins Provide Novel Serological Markers for Dementias?. International Journal of Alzheimer's Disease،Vol. 2012, no. 2012, pp.1-9.
https://search.emarefa.net/detail/BIM-454740
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Wang, Y.…[et al.]. Will Posttranslational Modifications of Brain Proteins Provide Novel Serological Markers for Dementias?. International Journal of Alzheimer's Disease No. 2012 (2012), pp.1-9.
https://search.emarefa.net/detail/BIM-454740
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Wang, Y.& Sørensen, M. G.& Zheng, Q.& Zhang, C.& Karsdal, Morten A.& Henriksen, K.. Will Posttranslational Modifications of Brain Proteins Provide Novel Serological Markers for Dementias?. International Journal of Alzheimer's Disease. 2012. Vol. 2012, no. 2012, pp.1-9.
https://search.emarefa.net/detail/BIM-454740
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-454740
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر